Showing 1671-1680 of 4063 results for "".
- Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitishttps://modernod.com/news/krystal-biotech-announces-first-patient-dosed-in-phase-12-trial-of-kb801-for-the-treatment-of-neurotrophic-keratitis/2482883/Krystal Biotech announced that the first patient has been dosed in its phase 1/2 clinical trial (EMERALD-1), a 2:1 randomized, double-masked, multicenter, placebo-controlled study evaluating KB801 for the treatment of neurotrophic keratitis (NK). KB801 is a redosable eye drop gene
- Oculis Announces Positive Phase 2 Results for OCS-05 in Acute Optic Neuritis as a Potential Neuroprotective Therapyhttps://modernod.com/news/oculis-announces-positive-phase-2-results-for-ocs-05-in-acute-optic-neuritis-as-a-potential-first-in-class-neuroprotective-therapy/2482597/Oculis announced positive topline results for OCS-05 in the phase 2 ACUITY trial for patients with acute optic neuritis. The trial met its primary endpoint of safety and achieved statistical significance on several key efficacy-based secondary endpoints. The phase 2 ACUIT
- Harrow Announces 52-Week Data from Vevye ESSENCE-2 Open-Label Extension Studyhttps://modernod.com/news/harrow-announces-52-week-data-from-vevye-essence-2-open-label-extension-study/2482309/Harrow has announced results from its ESSENCE‑2 open-label extension (OLE) clinical study for Vevye (cyclosporine ophthalmic solution) 0.1%, the first and only cyclosporine to treat the signs and symptoms of dry eye disease (DED). ESSENCE-2 OLE was a phase 3, prospective, multicent
- Qlaris Bio’s Novel IOP-Lowering Product, QLS‑111, is Dosed in Phase 2 Trialshttps://modernod.com/news/qlaris-bios-novel-iop-lowering-product-qls111-is-dosed-in-phase-2-trials/2482195/Qlaris Bio announced the initiation and dosing of two separate US phase 2 masked, randomized clinical trials investigating QLS‑111 in patients with ocular hypertension and glaucoma. “The start of these phase 2 trials represents a key milestone in our goal of bringing QLS‑111
- Oculis Begins Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgeryhttps://modernod.com/news/oculis-begins-phase-3-optimize-2-trial-of-ocs-01-for-the-treatment-of-inflammation-and-pain-following-cataract-surgery/2482022/Oculis Holding announced 'First Patient First Visit' (FPFV) in the OCS-01 phase 3 OPTIMIZE-2 trial for the treatment of inflammation and pain following cataract surgery. Data from the phase 3 OPTIMIZE-2 trial is intended to support the company’s NDA submission to the FDA. If ap
- Ocugen Announces First Patient Dosed in Phase 1/2 Trial of OCU410 Modifier Gene Therapy for GAhttps://modernod.com/news/ocugen-announces-first-patient-dosed-in-phase-12-trial-of-ocu410-modifier-gene-therapy-for-ga/2482006/Ocugen announced that the first patient has been dosed in the ArMaDa phase 1/2 clinical trial of OCU410 (AAV-RORA), a modifier gene therapy product candidate being developed for dry AMD (AMD). This phase 1/2 trial will assess the safety and efficacy of OCU410 for geographic at
- Ocuphire Pharma Announces End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathyhttps://modernod.com/news/ocuphire-pharma-announces-end-of-phase-2-meeting-with-fda-for-oral-apx3330-in-diabetic-retinopathy/2481935/Ocuphire Pharma announced the successful outcome of an end-of-phase 2 (EOP2) meeting with the FDA supporting the advancement of oral APX3330 for the treatment of diabetic retinopathy (DR) into phase 3 studies based on the recently completed phase 2 ZETA-1 trial. “We are
- Neurophth Announces First Patient Dosed in Phase 1/2 Clinical Trial of Second Gene Therapyhttps://modernod.com/news/neurophth-announces-first-patient-dosed-in-phase-12-clinical-trial-of-second-gene-therapy/2481786/Neurophth Therapeutics announced that the first patient has been dosed in the international multi-region, multicenter phase 1/2 clinical trial for the treatment of Leber hereditary optic neuropathy caused by ND1 mutation (ND1-LHON). Neurophth is conducting a phase 1/2, mu
- Bausch + Lomb Launches PreserVision AREDS 2 Formula Soft Gels Plus CoQ10 in the United Stateshttps://modernod.com/news/bausch-lomb-launches-preservision-areds-2-formula-soft-gels-plus-coq10-in-the-united-states/2481667/Bausch + Lomb announced the US launch of PreserVision AREDS 2 Formula soft gels plus coenzyme Q10 (CoQ10). Developed as a two-in-one option, Bausch + Lomb says PreserVision AREDS 2 Formula eye vitamins plus CoQ10 is the only eye vitamin that combines the exact nutrient formula
- Ocuphire Announces Phase 2 Topline Results of Oral Drug Candidate for Treatment of Diabetic Retinopathyhttps://modernod.com/news/ocuphire-announces-topline-results-from-zeta-1-phase-2-trial-of-oral-apx3330-in-diabetic-retinopathy/2481365/Ocuphire Pharma announced topline efficacy and safety results from its ZETA-1 phase 2 trial evaluating oral APX3330 for the treatment of diabetic retinopathy (DR). “Our goals in this initial retina phase 2 trial were to explore multiple endpoints to evaluate the potential for APX3